



Carol Cheng, COO

# Taiwan COVID-19 Pharmaceuticals in Development

	Product	Company	Type	Status	Country	*
1	Ropeginterferon alfa-2b (P1101)	PharmaEssentia	Antiviral Drug	Phase 3	TW	V
2	FP-025	Foresee Pharmaceutical	Anti-inflammatory and MMP-12 inhibitor	Phase 2/3	US	
3	Silmitasertib	Senhwa Biosciences	Antiviral Drug	Phase 2	US, IN	V
4	Antroquinonol	Golden Biotechnology	Antiviral Drug	Phase 2	US	V
5	AD17002	Advagene Biopharma	Immune Modulators	Phase 2	TW	
6	FB704A	Oneness Biotech	Anti-inflammatory	Phase 2	US	
7	Pentarlandir	SyneuRx	Antiviral Drug	Phase 2	US, TW	
8	TLC19	TLC	Antiviral Drug	Phase 1	AUS, TW	

\* Compassionate use

Source: TRPMA

# Taiwan COVID-19 MSCs Therapy in Development

Product	Company	Type	Indication	Status	Country	*
<b>HUCDMSCs</b>	<b>BIONET</b>	Umbilical cord-derived	Acute respiratory distress syndrome (ARDS)	Phase 2	TW	V
<b>UMSC01</b>	<b>Ever Supreme</b>	Umbilical cord-derived	Acute respiratory distress syndrome (ARDS)	Phase 1/2	US	V
<b>UMC119-06</b>	<b>Meridigen</b>	Umbilical cord-derived	Acute respiratory distress syndrome (ARDS)	Phase 1	TW, US	V

\* Compassionate use in Taiwan

Source: TRPMA

# COVID-19 Vaccines in Taiwan

## Local Developer

Company	Status, Country	Remarks
MVC	Phase 3, Paraguay	Taiwan EUA 8/16, 2021
UBI Pharma	Phase 3, India	-
Advagene Biopharma	IND	-

## Foreign Developer

Company	Status	National Vaccination program
AstraZeneca	Taiwan EUA	Yes
BioNTech	Taiwan EUA	Yes
Moderna	Taiwan EUA	Yes
Johnson & Johnson	Taiwan EUA	Not yet

